Dose Selection Strategies for First-in-Human Trials: From NOAEL to MABEL
Determining an appropriate starting dose for first-in-human (FIH) clinical trials is one of the most critical decisions in early-phase drug development. Regulatory guidance from the FDA and EMA encourages the use of scientifically grounded dose selection strategies that incorporate both preclinical toxicity findings and mechanistic pharmacology data. Traditionally, the No Observed Adverse Effect Level (NOAEL)…